* Amphastar Pharmaceuticals Inc AMPH.OQ AMPH.O is
expected
to show a rise in quarterly revenue when it reports results on
August 7 for the period ending June 30 2024
* The Rancho Cucamonga California-based company is expected
to
report a 17.3% increase in revenue to $170.944 million from
$145.71 million a year ago, according to the mean estimate from
6 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Amphastar
Pharmaceuticals Inc
is for earnings of 77 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 23.7%
in the last three months.
* Wall Street's median 12-month price target for Amphastar
Pharmaceuticals Inc is $66.00, above its last closing price
of $40.41.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 1.04 0.96 1.04 Beat 8.7
Dec. 31 2024 0.92 0.93 0.88 Missed -4.9
Sep. 30 2023 0.70 0.69 1.15 Beat 65.5
Jun. 30 2023 0.56 0.56 0.65 Beat 16
Mar. 0.47 0.48 0.62 Beat 30.4
31 2023
Dec. 31 2022 0.40 0.41 0.73 Beat 79.7
Sep. 30 2022 0.40 0.39 0.38 Missed -3.6
Jun. 30 2022 0.35 0.35 0.39 Beat 12.1
This summary was machine generated August 6 at 02:04 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)